A new development in veterinary science could change how we care for aging dogs. A drug called LOY-002, designed to extend the healthy lifespan of senior dogs, is one step closer to FDA approval. The pill is being developed by Loyal, a US-based biotech company focused on longevity in pets.
The drug is aimed at medium- to large-breed dogs over seven years old. Compared to lesser breeds, these dogs typically mature more quickly. According to Loyal, LOY-002 helps slow down aging by targeting hormones linked to metabolism and growth. It's meant to give older dogs more active and healthy years.
LOY-002 was granted "Reasonable Expectation of Effectiveness" classification by the FDA in December 2023. This is a big step forward. It means the drug has shown enough promise in early trials to continue testing. If all goes well, it could become available to veterinarians by the end of 2025.
The company is also running one of the largest longevity studies in dogs. The STAY study is tracking more than 1,000 senior dogs across the U.S. Half will receive the new pill, and the other half a placebo. The study will measure changes in both lifespan and quality of life.
Experts say the science behind the pill is promising. Dogs share many age-related diseases with humans. So, treatments that work for pets may also offer clues for human aging.
For pet parents, this could mean more time with their furry companions. A longer life filled with energy, fewer health issues, and more memories.
As the research continues, one thing is clear: the future of pet care is shifting. Science is helping us give our pets not just longer lives—but better ones too.
